2 days Ago By ABMN Staff
Envestnet Asset Management Inc. reduced its position in shares of Takeda Pharmaceutical Company Limited ( NYSE:TAK – Free Report ) by 31.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission.
The firm owned 984,678 shares of the company’s stock after selling 460,843 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Takeda Pharmaceutical were worth $13,037,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in TAK. Versant Capital Management Inc bought a new stake in Takeda Pharmaceutical during the fourth quarter valued at approximately $26,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Takeda Pharmaceutical during the 3rd quarter valued at $40,000.
BNP Paribas Financial Markets increased its stake in shares of Takeda Pharmaceutical by 416.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after purchasing an additional 2,596 shares in the last quarter.
Farther Finance Advisors LLC increased its stake in shares of Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock worth $47,000 after purchasing an additional 1,976 shares in the last quarter.
Finally, Crowley Wealth Management Inc. bought a new position in Takeda Pharmaceutical in the 4th quarter worth $52,000. Hedge funds and other institutional investors own 9.
17% of the company’s stock. Wall Street Analysts Forecast Growth Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, April 2nd. Takeda Pharmaceutical Price Performance NYSE TAK opened at $14.
67 on Thursday. The company has a current ratio of 1.31, a quick ratio of 0.
72 and a debt-to-equity ratio of 0.63. Takeda Pharmaceutical Company Limited has a 12 month low of $12.
58 and a 12 month high of $15.37. The stock has a market cap of $46.
68 billion, a price-to-earnings ratio of 36.68, a PEG ratio of 0.24 and a beta of 0.
39. The company’s 50 day moving average is $14.52 and its two-hundred day moving average is $13.
90. Takeda Pharmaceutical ( NYSE:TAK – Get Free Report ) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.
42 EPS for the quarter, beating the consensus estimate of $0.34 by $0.08.
Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%.
As a group, research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year. Takeda Pharmaceutical Profile ( Free Report ) Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. Featured Articles Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Company Limited ( NYSE:TAK – Free Report ).
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter ..
_0.jpg?itok=yAIF6nFK)
